Results 41 to 50 of about 12,566 (192)
Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis
VIEW, EarlyView.In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian +5 more
wiley +1 more source
Orlistat ameliorates lipid dysmetabolism in high-fat diet-induced mice via gut microbiota modulation
Frontiers in MicrobiologyOrlistat reduces obesity by inhibiting gastrointestinal lipases, thereby blocking the absorption and accumulation of triglycerides in the intestine. It has been shown to improve lipid metabolism and alter intestinal microbial communities in animals and ...
Chengyan Huang +7 more
doaj +1 more source
Serotonin Degradation and Lipid Metabolism Regulate Human Tc2 Cell Effector Functions
Allergy, EarlyView.Human Tc2 cells exhibit a metabolically active phenotype characterized by enhanced glycolysis, mitochondrial respiration, and fatty acid uptake dependent on PPARγ. Alarmins strongly amplify IL‐5 and IL‐13 production in Tc2 cells, supporting a shared immunometabolic program across type 2 lymphocytes.
Sabrina de Souza Ferreira +13 more
wiley +1 more source
Future Journal of Pharmaceutical Sciences, 2021 Background Most of the analytical methods reported for the estimation of Orlistat were complex, expensive, and deficient in reproducibility with no or very less informative regarding various statistical methods and equations used for the validation ...
Kiran Singh Sharma, Jagannath Sahoo
doaj +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Clinical Obesity, Volume 15, Issue 2, April 2025.Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet +3 more
wiley +1 more source
Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease
, 2017 Two patients developed kidney failure due to oxalate deposition in the kidney while taking orlistat. Cessation of orlistat was followed by partial recovery of kidney function.
Laurence Richard Solomon +7 more
core +1 more source
Patient Preference and Adherence, 2015 Oguz Ozcelik,1 Yusuf Ozkan,2 Sermin Algul,1 Ramis Colak2,3 1Department of Physiology, 2Department of Endocrinology and Metabolic Disease, Faculty of Medicine, Firat University, Elazig, 3Department of Endocrinology and Metabolic Disease, Faculty of ...
Ozcelik O, Ozkan Y, Algul S, Colak R
doaj
Clinical Obesity, Volume 15, Issue 2, April 2025.Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton +4 more
wiley +1 more source
Nutrition Journal, 2006 Background Orlistat is an anti-obesity drug licensed in the United Kingdom for 7 years. We present a case of a patient who developed pancreatitis four days after commencing orlistat.
Thomas Matthew, Napier Sarah
doaj +1 more source